Takeda Pharmaceutical (TAK) EBT (2017 - 2026)

Takeda Pharmaceutical's EBT history runs 10 years deep, the most recent figure standing at -$2.9 billion for Q1 2026.

• On a quarterly basis, EBT fell 393.93% year-over-year to -$2.9 billion in Q1 2026; TTM through Mar 2026 was -$2.9 billion, a 195.36% decrease from a year earlier, with the FY2026 full-year figure at -$945.7 million, down 182.28% from the prior year.
• EBT grew to -$2.9 billion in Q1 2026 per TAK's latest filing, from -$3.0 billion in the prior quarter.
• Across five years, EBT topped out at $2.3 billion in Q3 2023 and bottomed at -$3.0 billion in Q4 2025.
• The 5-year median for EBT is $921.8 million (2024), against an average of $597.7 million.
• Across the five-year window, EBT jumped 384.77% in 2023 and sank 393.93% in 2026, its largest moves.
• Year by year, EBT stood at $758.5 million in 2022, then slumped by 57.27% to $324.1 million in 2023, then sank by 317.8% to -$705.8 million in 2024, then slumped by 318.9% to -$3.0 billion in 2025, then rose by 1.86% to -$2.9 billion in 2026.
• Per Business Quant, the three latest TAK EBT figures stand at -$2.9 billion (Q1 2026), -$3.0 billion (Q4 2025), and $2.1 billion (Q3 2025).